Deutsche Bank analyst Emmanuel Papadakis downgraded Sanofi to Sell from Hold.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SNY:
- Sanofi completes acquisition of Provention Bio
- Sanofi confirms FY23 business EPS view of up low single digits at CER
- Sanofi reports Q1 business EPS EUR 2.16, up 11.9% at CER
- Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention
- ALX Oncology enters clinical trial collaboration with Sanofi